Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Aldeyra Therapeutics Inc ALDX

Healthcare Biotechnology
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ALDX)

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement

Business Wire 3 days ago

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Business Wire 7 days ago

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Business Wire October 31, 2024

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Business Wire October 3, 2024

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire September 5, 2024

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Business Wire August 8, 2024

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Business Wire August 7, 2024

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Business Wire June 20, 2024

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Business Wire June 13, 2024
View More News ››

Opinion & Analysis (NDAQ:ALDX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:ALDX)

Aldeyra Therapeutics Announces FDA Acceptance for Review of

News; $ALDX Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye...
whytestocks - 3 days ago

ALDX.....LoL....even The Pumpers are pumping their book

on this "Train Wreck" Sheesh
Iseneschal - October 16, 2023

WILL ALDEYRA HIT THE BULL’S EYE IN DRY EYE?

$ALDX    Excited to share our latest coverage on Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) which announced positive...
AviseAnalytics - July 19, 2022

it's a buy today for me

missed the bottom,but it is way oversold,so paid $5.76 per share and looking for a quick rebound of this one glta shareholders.
coolfooldumbguy - June 25, 2019

positive results

we will see what happens in April with this stock,so glta.
coolfooldumbguy - March 31, 2019

RE:watching this one for

Maybe i should of waited too. Dont understand why it didnt go up higher and why its giving back all its gains
Torontoinvestor - March 28, 2019
View more Bullboard ››

Nextleaf Solutions Ltd

Nextleaf Solutions Ltd

Nextleaf Solutions Ltd. is a cannabis processor with a portfolio of federally regulated emerging consumer brands, market ...
View More »